Can Fite BioPharma Stock Price

-0.1315 (-10.87%)
Upgrade to Real-Time
Regular Market
Volume 509,445
Bid Price
Ask Price
News -
Day High 1.1999


52 Week Range


Day Low 1.07
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Can Fite BioPharma Ltd CANF AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.1315 -10.87% 1.0785 12:23:37
Open Price Low Price High Price Close Price Prev Close
1.19 1.07 1.1999 1.21
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
965 509,445 $ 1.14 $ 579,117 - 0.9402 - 4.39
Last Trade Time Type Quantity Stock Price Currency
12:26:14 25 $ 1.0715 USD


Draw Mode:

Can Fite BioPharma Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 29.33M 27.19M 27.19M $ 763.00k $ - -1.20 -2.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - -

more financials information »

Can Fite BioPharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CANF Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.311.36491.071.25565,845-0.2315-17.67%
1 Month1.361.471.071.391,904,509-0.2815-20.7%
3 Months1.552.600.94021.924,288,002-0.4715-30.42%
6 Months2.182.600.94021.912,023,404-1.10-50.53%
1 Year1.994.390.94022.332,104,059-0.9115-45.8%
3 Years1.168.87650.382.221,132,561-0.0815-7.03%
5 Years1.998.87650.382.19725,227-0.9115-45.8%

Can Fite BioPharma Description

Can Fite Biofarma Ltd is a clinical-stage biopharmaceutical company. The company is focused on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune inflammatory indications, oncology and liver diseases as well as sexual dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention. The company's pipeline drugs are synthetic, specific agonists and allosteric modulators targeting the A3AR. All drugs are orally bioavailable with an excellent safety profile.

Your Recent History
Can Fite B..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.